AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03188783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 tablets orally, either a single dose or twice-daily.
Study NCT03188783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
Study NCT00869128 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Circadin
Description: 2 mg prolonged-release melatonin
Study NCT00869128 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT03240276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ICSI procedure for sperm injection into oocyte
Description: The ICSI procedure is the standard procedure of selection and injection of sperm into oocytes
Study NCT03240276 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MSOME
Description: Selection of ultramorphologically normal spermatozoa using an inverted microscope with 6300x magnification
Study NCT03240276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IMSI Procedure
Description: Injection of sperm that has been selected by the MSOME method into oocytes
Study NCT00282685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraarterial bone marrow progenitor cell transplantation
Description: catheter delivery of stem cells
Study NCT04529317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa and quinoa-based food
Description: Products created replaced grains, legumes, tubers, also farinaceous commonly consumed by the participants and only the cereal fraction was modified, similar products based on quinoa flour were created.~Thus, apart from delivering quinoa, quinoa flakes and quinoa flour to the participants, they were given products created with ≥70% quinoa flour and were biscuits, crackers, brioche, sponge cake, baguette bread, sliced bread and pasta. Moreover, a quinoa-based recipe was delivered with eight commonly consumed recipes that replaced the tuber, legume or grain of the recipe. Each subject received the equivalent of what they consumed according to their regular diet dietary records.
Study NCT04087369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled NCD WHO PEN Intervention
Description: In the intervention includes the planned roll-out of the World Health Organization's Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low resource settings by the Government of Nepal, Ministry of Health and Population. In addition, this intervention will include three evidence-based components: 1) non-communicable disease (NCD) care integration using mid-level practitioners (MLPs) and community healthcare workers (CHWs); 2) clinical decision support (CDS) tools to ensure quality care in accordance with best practices; and 3) training and supervision of MLPs to provide motivational interviewing (MI) techniques for modifiable risk factor optimization, with a specific focus on tobacco and alcohol use.
Study NCT02400619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shock waves
Description: Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
Study NCT02400619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Botulinum toxin type A Botox
Study NCT00311922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Literacy/Numeracy oriented educational intervention
Description: Comprehensive educational Intervention
Study NCT00311922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Receives comprehensive education that is not literacy/numeracy sensitive
Study NCT04262011 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate treatment
Description: Patients allocated to the immediate treatment group will receive full mouth treatment, and will use 0.12% chlorhexidine mouthwash, every 12 hours for a week, and will receive oral hygiene instructions throughout the follow-up period. Patients will be evaluated at the beginning, at 3 and 6 months.
Study NCT04262011 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: postponed treatment
Description: Patients allocated to the late treatment group will be assessed at baseline, 3 and 6 months. After the end of the follow-up period, they will receive non-surgical periodontal treatment performed in four sessions.
Study NCT02022735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulator
Description: DBS will provide brain stimulation.
Study NCT01136564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar
Description: 2 capsules of 1 microgram daily
Study NCT01136564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules daily
Study NCT04693078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI polyp detection system based on deep learning
Description: A Polyp detection system based on deep learning and artificial intelligence, which can alert the operator in real-time to the presence and location of polyps during a colonoscopy.
Study NCT04692116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate treatment
Description: Subthalamotomy using the ExAblate
Study NCT01670045 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab in accordance with the licensed label recommendation.
Study NCT03338283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromassage
Description: Electro-massage that will be performed by a specialist physiotherapist with more than 8 years of experience We use ENDOMED 482 (Enraf Nonius, Spain) for the elecro-massage. the current parameters are: frequency shift at 4000 Hz IFC, 100 Hz AMF in CV mode. We will gradually raise the current intensity until reaching a high level, but not so high as to cause pain or discomfort, nor evident muscle contraction, although a gentle vibration is allowed. The electro-massage was performed on the musculature of the shoulder and neck.
Study NCT03338283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservatory treatment
Description: The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
Study NCT00614978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib and temozolomide
Description: Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.
Study NCT03992833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung cancer screening
Description: In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.~The simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume \< 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume > 300 mm3 (positive).
Study NCT05039125 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic cavitation
Description: * From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments.~* Part III: 3cm above the umbilicus to 2cm below the umbilicus~* After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head.~* The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased.~* The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes.~* After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton.~For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months.~For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months
Study NCT02766036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propolis
Description: Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses
Study NCT02766036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 500 mg / day of the placebo in the form of tablets split in two daily doses
Study NCT01831271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prescribed physical activity
Description: Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
Study NCT01831271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neck specific training
Description: The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
Study NCT00704977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique
Description: The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs.
Study NCT02364076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administration of 200 mg MK-3475 once every 3 weeks
Study NCT02364076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: 100mg taken by mouth twice daily
Study NCT00420628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loteprednol etabonate/tobramycin opthalmic suspension
Description: Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
Study NCT00420628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
Study NCT01372540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT01372540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filanesib
Description: Given IV
Study NCT01372540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04331509 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT02088892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG SSI
Description: Intradermal injection
Study NCT02088892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Tice
Description: Intradermal injection
Study NCT00470561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Two 325 mg doses of aspirin per day for 6 months
Study NCT00470561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo pills per day for 6 months
Study NCT02193555 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A, Senofilcon A
Description: 1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
Study NCT04839666 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Perioperatively propofol administration
Study NCT04693299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: colonoscopy
Description: A colonoscopy scheduled within the normal pathway of care will be performed. No interventions will be performed.
Study NCT01014195 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive and behavioral evaluation
Description: The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
Study NCT04350047 — intervention group
Intervention type: PROCEDURE
Intervention: Radical nephrectomy with inferior vena cava thrombectomy without thoracotomy
Description: The abdomen was accessed through a Makuuchi incision. After mobilization of the liver and assessment of the inferior vena cava infiltration (IVC), IVC was clamped below the level of the renal veins. In order to get access to the intrapericardial IVC, an incision was made through the tendon of the diaphragm and a clamp was placed first in the hepatoduodenal ligament (Pringle maneuver) and then in the endopericardial portion of the IVC, in that order. A longitudinal 3-4 cm incision was made incorporating the junction of IVC and right renal vein. After tumor removal thrombus was removed and a fine clamp was placed at the IVC just below the hepatocaval junction and immediate release of the clamping of the hepatoduodenal ligament. Total endopericardial clamp time was 4 minutes. Patients then underwent radical nephrectomy in a standard fashion with en bloc resection of the IVC thrombus.
Study NCT02723448 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: aclarubicin
Description: Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.
Study NCT03109626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Study NCT03109626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: DHA
Study NCT03790865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livoletide
Description: Daily subcutaneous injection
Study NCT03790865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous injection
Study NCT00096538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir
Study NCT04633499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognition Task
Description: Two paradigms will be tested: visual perspective taking and reading the mind in the eyes.
Study NCT04633499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition Task
Description: Two paradigms will be tested: visual perspective taking and reading the mind in the eyes.
Study NCT04633499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS either over the dmPFC or the rTPJ.
Study NCT04633499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS either over the dmPFC or the rTPJ.
Study NCT01634308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novosis(bongros/BMP-2)
Study NCT01634308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bio-oss
Study NCT04293497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytology staining
Description: Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained using endoscopic ultrasound-guided fine needle aspiration. Three types of slides (direct smear, thinprep, surepath) are prepared for staining.~1. conventional cytology staining method~2. new cytology staining method using antibody of methionyl-tRNA synthetase 1
Study NCT02171117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microtransplantation
Description: infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
Study NCT02171117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-mismatched donor peripheral stem cell infusion
Study NCT02741375 — intervention group
Intervention type: DEVICE
Intervention: Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA)
Description: All patients underwent at least 6-h NIRS monitoring using a Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA) cerebral oximeter in order to determined cerebral oximetry changes.
Study NCT01429298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 2 mg IV hydromorphone over to 2-3 minutes
Study NCT01429298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Attending administers IV opioid of his choosing
Study NCT02852057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: timolol maleate and dorzolamide hydrochloride
Description: Timolol maleate and dorzolamide hydrochloride loaded contact lenses
Study NCT02629744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.
Study NCT02629744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled Auto-injector (Rotaject)
Description: Participants self-administered etrolizumabSC injection using a prefilled auto-injector.
Study NCT03075189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplement
Description: During hospitalization the intervention group will receive a whey protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Both groups have diet registration and testing at baseline, discharge and follow-up.
Study NCT02581033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Analogue therapy
Description: Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
Study NCT00844662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermagate
Description: Film coated tablet 500mg
Study NCT00844662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer hydrochloride
Description: Tablet 800mg
Study NCT04633993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCSMP
Description: This study divided the patient-centered self-management manual for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
Study NCT02182219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120